

Calliditas Therapeutics - Recent weakness a great opportunity; raising valuation

Despite scoring on the primary and secondary endpoints in its phase III topline readout, Calliditas' shares have suffered and are now trading in Bear territory. In our view, the stock market fails to recognise Calliditas' emerging transformation into a commercial-stage biopharma. Following a review of this exciting case, we are even raising our Base Case to SEK 280 (250) per share.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Calliditas Therapeutics - Recent weakness a great opportunity; raising valuation